跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 36,023 条关于
“EpCAM-positive carcinomas”
全部
36,023
临床试验
26,039
药物
193
机构
8
资讯
9,783
去年
Lindis Biotech and Pharmanovia Partner to Relaunch Catumaxomab for Malignant Ascites
去年
CHMP Recommends Approval of Lindis Biotech's Korjuny (catumaxomab) for Malignant Ascites
9个月前
Pharmanovia Launches First-in-Class Korjuny (Catumaxomab) in Germany for Malignant Ascites Treatment
去年
Catumaxomab Receives European Marketing Authorization for Malignant Ascites Treatment
去年
Pharmanovia In-Licenses Catumaxomab for Malignant Ascites Treatment
去年
BI 764532 T-Cell Engager Shows Promise in DLL3-Positive Neuroendocrine Carcinomas with 29% Response Rate
去年
Lenvatinib Plus Gefitinib Shows Promise in Lenvatinib-Resistant Hepatocellular Carcinoma
2年前
CytomX Therapeutics Reports Promising Interim Phase 1 Data for CX-2051 Antibody-Drug Conjugate
去年
CytomX's CX-2051 Shows Promising 28% Response Rate in Advanced Colorectal Cancer Phase 1 Trial
5个月前
SBP Group's M701 Bispecific Antibody Receives NDA Acceptance for Malignant Ascites Treatment
第 1 页,共 979 页
上一页
下一页